Cyteir Therapeutics Inc

NASDAQ CYT

Download Data

Cyteir Therapeutics Inc EBIT to Total Assets Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2023: 43.67%

Cyteir Therapeutics Inc EBIT to Total Assets Ratio 1 year YoY Change (%) is 43.67% for the Trailing 12 Months (TTM) ending September 30, 2023, a -16.60% change year over year. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Cyteir Therapeutics Inc EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -0.07, a 52.36% change year over year.
  • Cyteir Therapeutics Inc EBIT to Total Assets Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -0.15.
NASDAQ: CYT

Cyteir Therapeutics Inc

CEO Mr. Joseph S. Zakrzewski
IPO Date June 18, 2021
Location United States
Headquarters 128 Spring Street, Lexington, MA, United States, 02421
Employees 46
Sector Healthcare
Industry Biotechnology
Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email